Creative Medical Technology Holdings, Inc. Fair Value Assumptions, Expected Dividend Rate (Deprecated 2018-01-31)
Creative Medical Technology Holdings, Inc. (CELZ) reported Fair Value Assumptions, Expected Dividend Rate (Deprecated 2018-01-31) of 0.00% for the 3-month period ending 2018-03-31, per its 10-Q filed 2018-08-03.
Discontinued › Notes › Fair Value Measures and Disclosures
us-gaap:FairValueAssumptionsExpectedDividendRate · last filed 2018-08-03
- Creative Medical Technology Holdings, Inc. fair value assumptions, expected dividend rate (deprecated 2018-01-31) for the quarter ending 2018-03-31 was 0.00%.
- Creative Medical Technology Holdings, Inc. fair value assumptions, expected dividend rate (deprecated 2018-01-31) for fiscal 2017 was 0.00%.
| Period end | Fair Value Assumptions, Expected Dividend Rate (Deprecated 2018-01-31) 3 month | Fair Value Assumptions, Expected Dividend Rate (Deprecated 2018-01-31) 6 month | Fair Value Assumptions, Expected Dividend Rate (Deprecated 2018-01-31) 9 month | Fair Value Assumptions, Expected Dividend Rate (Deprecated 2018-01-31) 12 month |
|---|---|---|---|---|
| 2018-03-31 | 0.00% 10-Q · filed 2018-08-03 | |||
| 2017-12-31 | 0.00% 10-K · filed 2018-03-29 | |||
| 2017-09-30 | 0.00% 10-Q · filed 2017-11-13 | |||
| 2017-06-30 | 0.00% 10-Q · filed 2017-08-14 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| AIM ImmunoTech Inc. (AIM) | United States | $0.006B | |
| CERO THERAPEUTICS HOLDINGS, INC. (CERO) | United States | $0.007B | |
| PharmaCyte Biotech, Inc. (PMCB) | United States | $0.005B | |
| TScan Therapeutics, Inc. (TCRX) | United States | $0.008B | -1.23 |
| WINDTREE THERAPEUTICS INC /DE/ (WINT) | United States | $0.003B | -0.32 |
| VivoSim Labs, INC. (VIVS) | United States | $0.003B | |
| Calidi Biotherapeutics, Inc. (CLDI) | United States | $0.003B | |
| CURIS INC (CRIS) | United States | $0.002B | -0.05 |
| Senti Biosciences Holdings, Inc. (SNTI) | United States | $0.011B | -0.70 |
| Silexion Therapeutics Corp (SLXN) | $0.001B |